Skip to main content
SpringerLink
Log in

FGF23: instability may affect accuracy and interpretation

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA (2011) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. doi:10.1007/s00198-011-1838-0

  2. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG (2012) FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 27:727–733

    Article  PubMed  CAS  Google Scholar 

  3. Manghat P, Souleimanova I, Cheung J et al (2011) Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone 48:1127–1132

    Article  PubMed  CAS  Google Scholar 

  4. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G (2010) Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21:1853–1861

    Article  PubMed  CAS  Google Scholar 

  5. Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592

    Article  PubMed  CAS  Google Scholar 

  6. Smith ER, Ford ML, Tomlinson LA, Weaving G, Rocks BF, Rajkumar C, Holt SG (2011) Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta 412:1008–1011

    Article  PubMed  CAS  Google Scholar 

  7. Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, Stumpf UC (2009) Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab 55:144–152

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Renal Medicine, Eastern Health Clinical School, Faculty of Medicine, Nursing & Health Sciences, Monash University, Level 2, 5 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia

    E. R. Smith, L. P. McMahon & S. G. Holt

Authors
  1. E. R. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. P. McMahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. G. Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. R. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, E.R., McMahon, L.P. & Holt, S.G. FGF23: instability may affect accuracy and interpretation. Osteoporos Int 24, 1135–1136 (2013). https://doi.org/10.1007/s00198-012-2036-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-2036-4

Keywords

Search

Navigation